6

Notice of Allowability	Application No.	Applicant(s)
	10/511,102	TSUCHIKAWA ET AL.
	Examiner	Art Unit
	Ives Wu	1724
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
I. X This communication is responsive to <u>10/3/06</u> .		
2. ⊠ The allowed claim(s) is/are <u>1-16</u> .		
Acknowledgment is made of a claim for foreign priority ur a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. A SUBSTITUTE OATH OR DECLARATION must be subminformal PATENT APPLICATION (PTO-152) which give	e been received. be been received in Application No cuments have been received in this in of this communication to file a reply of this application.	national stage application from the complying with the requirements S AMENDMENT or NOTICE OF
5. CORRECTED DRAWINGS (as "replacement sheets") mus		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t	.84(c)) should be written on the drawir he header according to 37 CFR 1.121(c	ngs in the front (not the back) of d).
5. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		·
1. ⊠ Notice of References Cited (PTO-892)	5. Notice of Informal P	· ·
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	 Interview Summary Paper No./Mail Dat 	ie
3. 🛮 Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>I 0/3</u> / 06	7. 🗌 Examiner's Amendr	nent/Comment
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
	9. Other	

Art Unit: 1724

DETAILED ACTION

(1). Applicants' Amendments, Remarks and Affidavits filed on October 3, 2006 have been received.

Claim 2 is amended. Claims 13-16 are newly added.

The rejections of claims 1-14 in prior Office Action dated April 3, 2006 is withdrawn in response to the Affidavits filed on October 3, 2006.

Allowable Subject Matter

(2). Claims 1 - 16 are allowed.

Reasons for Allowance

(3). The following is a statement of reasons for the indication of allowable subject matter: The instant application is allowable in view of applicants' Affidavits to the fact that prior art references do not possess the dielectric constant less than 3.0 at 1GHz or more, even not in combined teachings. The closest prior art reference Tsuchikawa et al (US006667107B2) do not disclose the properties of dielectric constant less than 3.0 when the disubstituted phosphinic acid of Kawase et al (US003953539) or Ernst (US003046231) is combined, provided by the Comparative Examples 7-10 in the Table 1 in Affidavits filed on October 3, 2006. Since Tsuchikawa et al (US006667107B2) is closer reference than Wrezel et al (US004777227). Such evidence as provided by applicants' would overcome disputes or inferences of obviousness. Accordingly, the rejection in previous Office Action dated April 3, 2006 is withdrawn.

Accordingly, instant claims 1 - 16 are allowable subject matter and passed to issue.

As of the date of this Notice of Allowability, the Examiner has not located or identified any reference that can be used singularly or in combination with another reference including cited references hereinbefore to render the present invention anticipated or obvious to one of ordinary skill in the art.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Art Unit: 1724

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ives Wu whose telephone number is 571-272-4245. The examiner can normally be reached on 8:00 - 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Duane Smith can be reached on 571-272-1166. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Examiner: Ives Wu Art Unit: 1724

Date: December 5, 2006

DUANE SMITH
PRIMARY EXAMINER

1.)-1.)-66

Page 3